The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention provides compounds, compositions thereof, and methods of using the same.

Disclosed herein, inter alia, are compounds for inhibiting N-MYC or Aurora A Kinase and uses thereof.

Disclosed herein, inter alia, are compounds for inhibiting N-MYC or Aurora A Kinase and uses thereof.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.